Oncology Institute entered into a $75 million senior secured term loan with OrbiMed and executed a related Pledge and Security Agreement granting a first-priority lien on substantially all assets. The facility, drawn in full at closing on Jul 01 2026, matures on Jul 01 2031 and carries a floating monthly rate tied to one-month Term SOFR with an additional margin. Proceeds, along with cash on hand, were used to fully repay the company’s 4% senior secured convertible notes due 2027, extending maturities and enhancing liquidity.
Agreement 1: Oncology Institute Secures $75 Million OrbiMed Term Loan, Repays 2027 Convertible Notes
- Agreement type: First-lien senior secured term loan facility
- Counterparty: OrbiMed Opportunities (CA) V, as Administrative Agent, and other lenders
- Signed / Effective: Jul 01 2026 / Jul 01 2026
- Duration / Termination: Through Jul 01 2031
- Reason: Refinance 2027 convertible notes and enhance liquidity
Agreement 2: Oncology Institute Enters Pledge and Security Agreement Granting First-Lien to OrbiMed
- Agreement type: Pledge and Security Agreement securing term loan obligations
- Counterparty: OrbiMed Opportunities (CA) V
- Signed / Effective: Jul 01 2026 / Jul 01 2026
- Duration / Termination: Through loan maturity
- Reason: Provide collateral support for new loan facility
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.